Drug-Induced Alopecia Areata From Upadacitinib

August 2024 in “ Cureus ”

Alexander H Chang, Nicholas Brownstone, Sylvia Hsu

alopecia areata upadacitinib drug-induced alopecia atopic dermatitis

Studysummary In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before. Our plain-language summary of this paper — not a Tressless recommendation.

A 55-year-old woman developed alopecia areata (AA) approximately one year after starting treatment with upadacitinib for atopic dermatitis, as described in this case report. This occurrence suggests a potential link between upadacitinib and drug-induced AA, a connection not previously documented in the literature. The case underscores the need for further investigation into whether upadacitinib can cause AA, highlighting the typical timeline for drug-induced alopecia.

View this study on assets.cureus.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research Successful Treatment of Severe Atopic Dermatitis and Alopecia Universalis With Upadacitinib in a 29-Year-Old Male Patient

5 citations , May 2024 in “Journal of Allergy and Clinical Immunology Global”

In this case study, a 29-year-old male with severe atopic dermatitis and alopecia universalis experienced an excellent response to treatment with upadacitinib, indicating it may be a promising option for similar patients.

research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

March 2024 in “Clinical, cosmetic and investigational dermatology”

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

research Selective JAK 1 Inhibition With Upadacitinib as a Potential Treatment for Coexistent Severe Atopic Dermatitis and Alopecia Areata

4 citations , February 2024 in “Anais Brasileiros de Dermatologia”

research A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System

6 citations , January 2024 in “International Journal of Dermatology”

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

research Upadacitinib in Concurrent Crohn's Disease, Atopic Dermatitis, and Alopecia Areata: A Case Report

12 citations , July 2023 in “Journal of the European Academy of Dermatology and Venereology”

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

research Drug-Induced Alopecia Areata: A Systematic Review

3 citations , May 2023 in “Journal of the American Academy of Dermatology”

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

research Upadacitinib for Management of Recalcitrant Alopecia Areata: A Retrospective Case Series

3 citations , March 2023 in “JAAD case reports”

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

9 citations , January 2023 in “Dermatology and therapy”

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

research Successful Treatment of Concomitant Alopecia Universalis and Crohn's Disease with Upadacitinib: A Case Report

10 citations , January 2023 in “SAGE Open Medical Case Reports”

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

research Upadacitinib for the Treatment of Alopecia Areata and Severe Atopic Dermatitis in a Pediatric Patient: A Case Report

7 citations , January 2022 in “SAGE open medical case reports”

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.